hypertrophy

(redirected from Benign prostatic hypertrophy)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.

hypertrophy

(hīpûr`trəfē), enlargement of a tissue or organ of the body resulting from an increase in the size of its cells. Such growth accompanies an increase in the functioning of the tissue. In normal physiology the growth in size of muscles (e.g., in an athlete as a result of increased exercise) and also the enlargement of a uterus in pregnancy are caused by hypertrophy of muscle cells. In pathology the thickening of the heart muscle from overstrain, as in hypertensionhypertension
or high blood pressure,
elevated blood pressure resulting from an increase in the amount of blood pumped by the heart or from increased resistance to the flow of blood through the small arterial blood vessels (arterioles).
..... Click the link for more information.
 (high blood pressure), is the result of hypertrophy. An organ subjected to extra work (e.g., the one kidney left to function after surgical removal of the other) usually compensates by enlarging; in such cases hyperplasia, an increase in the number of cells, generally accompanies hypertrophy.

Hypertrophy

 

an increase in the volume of a body organ or of any of its parts.

Hypertrophy in man (or in animals) may occur either as the result of the enlargement of the individual component elements of an organ (cells and tissues) or as the result of an increase in their quantity (hyperplasia). True hypertrophy and false hypertrophy are distinguished. The former includes enlargement in volume or mass of specific elements as the result of an increased functional load (so-called functional, or compensatory, hypertrophy) or disruption of the regulatory influences of the nervous and endocrine systems. Functional hypertrophy may appear in healthy persons who are occupied with physical labor, such as in athletes (“physiologic hypertrophy” of the muscles). It may also appear upon affection of a part of any organ, such as after heart failure (compensatory hypertrophy) or after the destruction of a paired organ, such as a kidney (vicarious hypertrophy). Compensation for the impaired functions occurs in all instances of functional hypertrophy. Examples of hypertrophy occurring as a result of the disruption of neuroendocrine influences include acromegaly and gynecomastia; in these cases the hypertrophy has no compensatory significance but is accompanied by considerable disturbances of function. False hypertrophy refers to enlargement of the organ as the result of excessive growth of the interstitial, most often the adipose, tissue in response to atrophy of the parenchyma (the functional tissue). Function of the organ in such cases is usually decreased.

L. L. SHIMKEVICH

Hypertrophy of plant organs is the result of an increase in the size of their cells. The hypertrophy may be the effect of increased synthesis of the substances of the cell membrane or cytoplasm, deposits of reserve compounds, or the development of polynucleosis or polyploidy. The causes of hypertrophy include disruption of the synthesis and metabolism of phenol compounds, amino acids, proteins, carbohydrates, and fats, as well as deficiency of trace elements. The condition may also be caused by viruses, bacteria, fungi, invertebrates, and plant parasites. It may accompany many mutations, grafts, and the effects on the plant of ionizing radiation or ultrasound. Hypertrophy is usually interconnected with hyperplasia and disruptions of tissue differentiation in the organs. In many instances (for example, when there is development of tumors or galls) hypertrophy follows cell division; after mechanical injury and physical or chemical effects, however, it is often primary. Hypertrophy is observed in higher as well as in lower plants.

E. I. SLEPIAN

hypertrophy

[hī′pər·trə·fē]
(pathology)
Increase in cell size causing an increase in the size of an organ or tissue.

hypertrophy

enlargement of an organ or part resulting from an increase in the size of the cells
References in periodicals archive ?
Synaptic has been issued United States patents covering the alpha-1a adrenergic receptor and the use of selective alpha-1a antagonists for the treatment of benign prostatic hypertrophy.
Although it has been used for a myriad of indications as diuretic, aphrodisiac and breast augmenter, its major clinical usage is in benign prostatic hypertrophy (BPH).
Benign prostatic hypertrophy and localized prostate cancer: Dartmouth Medical School, John E.
NasdaqGM:SPPI) today announced the completion of a 9-month, randomized, double-blind, placebo-controlled, Phase 2b study of the safety and efficacy of ozarelix, the Company's drug candidate for the treatment of benign prostatic hypertrophy (BPH).
This model can also distinguish prostate cancer from benign prostatic hypertrophy and prostatitis-two non-cancerous conditions that lead to false-positive PSA test results-with an accuracy of 90%.
Dutasteride was approved for benign prostatic hypertrophy in men with an enlarged prostate in 2001.
It is often the presenting symptom of benign prostatic hypertrophy (BPH) with at least 70% of BPH patients complaining of nocturia.
An 80-year-old male with a medical history significant for type 2 diabetes mellitus, hypertension, coronary artery disease, hypothyroidism, and benign prostatic hypertrophy presented to the emergency room (ER) with a complaint of elevated blood sugar.
New drugs for benign prostatic hypertrophy and erectile dysfunction are closer to becoming available in the United States, now that a Food and Drug Administration expert panel has agreed that the QT-interval prolongation associated with the drugs is not clinically relevant.
In this survey 28%-35% of respondents indicated that they were using the product to treat a particular disease or condition; these included benign prostatic hypertrophy and anxiety (Lancet 361:101-06, 2003).
If it becomes enlarged, that's benign prostatic hypertrophy (BPH).
Based on the extensive DATTA evaluation published in JAMA, it is difficult to see how the phrase "not on an investigational basis" could be justified when applied to the application of transurethral balloon catheter dilation of the prostate for benign prostatic hypertrophy.

Full browser ?